Skye Bioscience Inc.(US:SKYE) Globenewswire·2026-01-15 19:58Core Viewpoint - Rosen Law Firm is reminding investors who purchased Skye Bioscience, Inc. securities during the Class Period from November 4, 2024, to October 3, 2025, of the January 16, 2026, lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - Investors who bought Skye securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by January 16, 2026 [2] - The lawsuit alleges that defendants made materially false and misleading statements regarding Skye's business and the effectiveness of its product, nimacimab, which led to overstated clinical and commercial prospects [4] Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company [3] - The firm has been ranked No. 1 for securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions of dollars for investors [3] - In 2019, the firm secured over $438 million for investors, showcasing its capability in handling such cases [3]